Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
about
Evolution of stimulants to treat ADHD: transdermal methylphenidateLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesSubjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant usersDevelopment of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primatesA linear model for estimation of neurotransmitter response profiles from dynamic PET data.Addiction: decreased reward sensitivity and increased expectation sensitivity conspire to overwhelm the brain's control circuitMethylphenidate increases choice of cigarettes over money.Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.Early and prolonged exposure to reward delay: effects on impulsive choice and alcohol self-administration in male ratsOsmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder.Imaging dopamine's role in drug abuse and addiction.OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.OROS methylphenidate hydrochloride for adult patients with attention deficit/hyperactivity disorder.A review of psychostimulant-induced neuroadaptation in developing animals.The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective.Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.Comparison of the pharmacokinetics and clinical efficacy of new extended-release formulations of methylphenidate.Appropriate experimental approaches for predicting abuse potential and addictive qualities in preclinical drug discovery.The safety of extended-release drug formulations for the treatment of ADHD.Exposure-response analyses of blood pressure and heart rate changes for methylphenidate in healthy adults.Deviant patterns of methylphenidate use in adults: a Danish nationwide registry-based drug utilization study.
P2860
Q22252903-02DB808E-466A-41D6-81A8-51260460F03BQ26822392-74761AB1-CA1D-47FD-806C-64BEE045020BQ28284151-6332BB9D-485C-4BE7-9ED6-DA010F6F3FABQ28393582-7FB16F10-5081-4F52-A9F1-31AFC48A545AQ33964638-2FF3B9B1-CA64-4E40-9656-04E137C68F51Q34132713-CAFBFA8E-71A7-4036-A18A-5CA95179A68FQ34406347-FAC05691-25DC-4516-82FC-3AC502284AA9Q35833310-9E74046E-B4F4-43F2-AECB-1F2E621795C7Q36939554-5A60EE5B-8653-47D6-986A-8FDD0A059449Q37184589-C48BEED3-2534-4FD0-8304-0B0A7EDA5EEEQ37212526-635EEB74-C1E2-46BF-9F70-F5C0D7C8A793Q37578475-4E98A2F8-58B7-46E4-82C8-DEDFFDB61A83Q37685508-5FB25883-8B84-4E30-BEDF-ACE983F506A6Q37827879-0FCF1092-104F-4C7D-8759-1E8B33541146Q37879918-684241C6-4FF2-4773-8F34-7D11FED6CEEBQ38027452-579F45D0-CD36-4E03-BCF7-D28FD77576C1Q38065287-8C4B93C1-DFF4-48CC-9F76-2B17713844A5Q38101134-B048F915-B948-4EAC-BBA3-406DA667F250Q38245151-C98466CA-C023-44A0-BDCA-BDC0F411501FQ38732635-8D08B948-73D2-488E-85BA-09CE080D5E58Q38953668-E28D9463-6CD2-4686-AD34-D87743C95AEDQ40638080-2A091B0E-22E5-41C9-80C6-3AF6B6C08334
P2860
Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Assessment of pharmacokinetics ...... enidate formulation in humans.
@ast
Assessment of pharmacokinetics ...... enidate formulation in humans.
@en
type
label
Assessment of pharmacokinetics ...... enidate formulation in humans.
@ast
Assessment of pharmacokinetics ...... enidate formulation in humans.
@en
prefLabel
Assessment of pharmacokinetics ...... enidate formulation in humans.
@ast
Assessment of pharmacokinetics ...... enidate formulation in humans.
@en
P2093
P356
P1476
Assessment of pharmacokinetics ...... enidate formulation in humans.
@en
P2093
Dolly A Parasrampuria
Kerri A Schoedel
Patrick Ciccone
Reinhard Schuller
Steven A Silber
P304
P356
10.1177/0091270007308615
P577
2007-10-25T00:00:00Z